Quanterix reports Q1 EPS (53c) vs (29c) last year

Reports Q1 revenue $30.3M, consensus $28.27M. “During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward,” said Masoud Toloue, CEO of Quanterix (QTRX). “Today, we are excited to announce a major advance: through a new early-access program, Simoa ONE assay kits will become compatible with over 20,000 existing flow cytometers worldwide-significantly reducing the need for capital equipment purchases by current and future customers. This leap is enabled by a breakthrough in reagent design: Simoa’s digital, ultra-sensitive detection now operates with kinetic dye-encoded beads, dramatically expanding our reach to an installed base more than twenty times the size of our own. We are democratizing access to ultrasensitive biomarker detection by meeting researchers where they are-a major step forward in our mission to bring Simoa to all labs.”